MCID: ACT113
MIFTS: 46

Acute Myeloblastic Leukemia with Maturation

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Acute Myeloblastic Leukemia with Maturation

MalaCards integrated aliases for Acute Myeloblastic Leukemia with Maturation:

Name: Acute Myeloblastic Leukemia with Maturation 52 58 17
Acute Myeloblastic Leukemia M2 52 58
Aml M2 52 58
Acute Myeloblastic Leukemia Type 2 52
Acute Myeloid Leukemia 71
Lam M2 52

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C92.0
UMLS via Orphanet 72 C1879321
Orphanet 58 ORPHA98834
UMLS 71 C1879321

Summaries for Acute Myeloblastic Leukemia with Maturation

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 98834 Definition A rare, acute myeloid leukemia characterized by evidence of granulocytic maturation and more than 20% of blast cells in the bone marrow and/or peripheral blood. The maturing non-blast granulocytic cells account for greater than or equal to 10% and monocytic cells less than or equal to 20% of the bone marrow cells. Various degrees of anemia , thrombocytopenia , or pancytopenia are present. Frequent clinical manifestations include fatigue, fever, bleeding disorders, and organomegaly, especially hepatosplenomegaly . Visit the Orphanet disease page for more resources.

MalaCards based summary : Acute Myeloblastic Leukemia with Maturation, also known as acute myeloblastic leukemia m2, is related to leukemia and pancytopenia. An important gene associated with Acute Myeloblastic Leukemia with Maturation is MIR181A1HG (MIR181A1 Host Gene), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 74 Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia... more...

Related Diseases for Acute Myeloblastic Leukemia with Maturation

Diseases related to Acute Myeloblastic Leukemia with Maturation via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 leukemia 29.4 NPM1 KIT FLT3
2 pancytopenia 29.3 KIT FLT3
3 myeloid leukemia 29.1 NPM1 KIT FLT3
4 leukemia, chronic myeloid 29.0 NPM1 KIT FLT3
5 leukemia, acute myeloid 28.9 NPM1 KIT FLT3
6 myelodysplastic syndrome 28.7 NPM1 KIT FLT3
7 hypereosinophilic syndrome 10.3
8 respiratory failure 10.1
9 exophthalmos 10.1
10 tetraploidy 10.1
11 autoimmune disease 10.0
12 hypertriglyceridemia, familial 10.0
13 lymphoma, hodgkin, classic 10.0
14 lymphoma, non-hodgkin, familial 10.0
15 follicular lymphoma 10.0
16 chromosomal triplication 10.0
17 partial duplication of chromosome 4 10.0
18 acute myeloblastic leukemia without maturation 9.9 NPM1 FLT3
19 cytogenetically normal acute myeloid leukemia 9.9 NPM1 FLT3
20 mesenchymal cell neoplasm 9.7 NPM1 KIT
21 acute myeloid leukemia with t(8;21)(q22;q22) translocation 9.7 KIT FLT3
22 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.7 KIT FLT3
23 core binding factor acute myeloid leukemia 9.7 KIT FLT3
24 8p11 myeloproliferative syndrome 9.7 KIT FLT3
25 mast cell neoplasm 9.6 KIT FLT3
26 myelodysplastic/myeloproliferative neoplasm 9.6 KIT FLT3
27 inflammatory myofibroblastic tumor 9.6 NPM1 KIT
28 myeloproliferative neoplasm 9.6 KIT FLT3
29 chronic eosinophilic leukemia 9.6 KIT FLT3
30 aggressive systemic mastocytosis 9.6 KIT FLT3
31 mastocytosis 9.6 KIT FLT3
32 chronic leukemia 9.6 KIT FLT3
33 blood platelet disease 9.5 KIT FLT3
34 leukocyte disease 9.4 KIT FLT3
35 polycythemia vera 9.3 KIT FLT3
36 cebpa-associated familial acute myeloid leukemia 9.3 NPM1 KIT FLT3
37 myeloid sarcoma 9.3 NPM1 KIT FLT3
38 childhood acute myeloid leukemia 9.3 NPM1 KIT FLT3
39 bone marrow cancer 9.3 NPM1 KIT FLT3
40 chronic myelomonocytic leukemia 9.3 NPM1 KIT FLT3
41 acute leukemia 9.3 NPM1 KIT FLT3
42 myelofibrosis 9.3 NPM1 KIT FLT3
43 wilms tumor 1 9.3 NPM1 KIT FLT3
44 hematologic cancer 9.2 NPM1 KIT FLT3
45 combined t cell and b cell immunodeficiency 9.2 KIT FLT3
46 leukemia, chronic lymphocytic 9.1 NPM1 KIT FLT3

Graphical network of the top 20 diseases related to Acute Myeloblastic Leukemia with Maturation:



Diseases related to Acute Myeloblastic Leukemia with Maturation

Symptoms & Phenotypes for Acute Myeloblastic Leukemia with Maturation

GenomeRNAi Phenotypes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.46 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.46 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.46 FLT3 KIT
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.44 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.44 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.44 KIT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.44 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.44 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.44 FLT3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.44 FLT3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.44 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.44 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.44 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.44 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.44 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.44 KIT
17 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.65 FLT3

MGI Mouse Phenotypes related to Acute Myeloblastic Leukemia with Maturation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.8 FLT3 KIT NPM1

Drugs & Therapeutics for Acute Myeloblastic Leukemia with Maturation

Drugs for Acute Myeloblastic Leukemia with Maturation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 529)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Lenalidomide Approved Phase 4 191732-72-6 216326
5 Dopamine Agents Phase 4
6 Psychotropic Drugs Phase 4
7 Neurotransmitter Agents Phase 4
8 Antidepressive Agents Phase 4
9 Central Nervous System Stimulants Phase 4
10 Cholinergic Agents Phase 4
11 Nicotinic Agonists Phase 4
12 Imatinib Mesylate Phase 4 220127-57-1 123596
13 Angiogenesis Inhibitors Phase 4
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
15
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
22
Ribavirin Approved Phase 3 36791-04-5 37542
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Acyclovir Approved Phase 3 59277-89-3 2022
27
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
28
Clove Approved Phase 2, Phase 3 84961-50-2
29
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
30
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
31
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
32
Enalaprilat Approved Phase 3 76420-72-9 6917719
33
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
34
Dalteparin Approved Phase 3 9005-49-6
35
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
36
Tazobactam Approved Phase 3 89786-04-9 123630
37
Vancomycin Approved Phase 3 1404-90-6 14969 441141
38
Piperacillin Approved Phase 3 66258-76-2 43672
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Thioguanine Approved Phase 3 154-42-7 2723601
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
Atorvastatin Approved Phase 3 134523-00-5 60823
43
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
44
Captopril Approved Phase 3 62571-86-2 44093
45
Nalbuphine Approved Phase 3 20594-83-6 5311304 5360630
46
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
47
Hydroxyurea Approved Phase 3 127-07-1 3657
48
Mercaptopurine Approved Phase 3 50-44-2 667490
49
Danazol Approved Phase 2, Phase 3 17230-88-5 28417
50
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 2336)
# Name Status NCT ID Phase Drugs
1 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
2 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
4 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
5 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
7 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
9 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
10 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
11 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
12 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
13 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
14 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
15 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
18 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
19 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
20 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
21 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
22 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
23 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
24 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
25 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
26 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
27 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
28 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
29 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
30 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
31 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
32 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
33 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
34 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
35 Phase III Clinical Trial of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
36 A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
37 Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML Unknown status NCT01696084 Phase 3 CPX-351;7+3 (cytarabine and daunorubicin)
38 The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients Unknown status NCT01633099 Phase 3 Decitabine
39 Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia Unknown status NCT02985372 Phase 3 Decitabine;Cytarabine
40 Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
41 A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
42 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
43 Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
44 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
45 Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years Unknown status NCT02140242 Phase 3 study part 1 - dose daunorubicin
46 Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2 Unknown status NCT00149162 Phase 3 proleukin
47 Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
48 Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Unknown status NCT01417767 Phase 2, Phase 3 CHG regimen;5-aza-deoxycytidine
49 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
50 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI

Search NIH Clinical Center for Acute Myeloblastic Leukemia with Maturation

Genetic Tests for Acute Myeloblastic Leukemia with Maturation

Anatomical Context for Acute Myeloblastic Leukemia with Maturation

MalaCards organs/tissues related to Acute Myeloblastic Leukemia with Maturation:

40
Myeloid, T Cells, Bone, Bone Marrow, Nk Cells, Testes, B Cells

Publications for Acute Myeloblastic Leukemia with Maturation

Articles related to Acute Myeloblastic Leukemia with Maturation:

(show top 50) (show all 469)
# Title Authors PMID Year
1
Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients. 61
32056080 2020
2
Acute myeloid leukemia with inversion of chromosome 16: cytological, immunophenotypic and cytogenetic disruption. 61
32319947 2020
3
Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center. 61
31725954 2020
4
Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia. 61
32362604 2020
5
Vulvar myeloid sarcoma as the presenting symptom of acute myeloid leukemia: a case report and literature review of Chinese patients, 1999-2018. 61
31699112 2019
6
Unusual Karyotype in Acute Myelomonocitic Leukemia: A Case Report. 61
31366525 2019
7
New perspectives on treatment strategies for patient with acute myeloid leukemia and complex karyotype abnormalities after percutaneous coronary intervention: A case report. 61
31348297 2019
8
Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement. 61
30848074 2019
9
[Donor HSCs with a preexisting ASXL1-mutation evoluting FLT3-ITD positive AML-M2 and FLT3-ITD negative AML-M5 in the donor and recipient respectively: one case analysis and literatures review]. 61
31104446 2019
10
Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report. 61
30921216 2019
11
The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter. 61
30637949 2019
12
Isolated myeloid sarcoma of the temporal bone: As the first clinical manifestation of acute myeloid leukemia in a patient of down's syndrome. 61
31015077 2019
13
Expression Analysis of PVT1, CCDC26, and CCAT1 Long Noncoding RNAs in Acute Myeloid Leukemia Patients. 61
30222365 2018
14
Polymorphisms of the CYR61 gene in patients with acute myeloid leukemia in a Han Chinese population. 61
30142822 2018
15
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. 61
29286103 2018
16
[Clinical Study of Patients with Myelodysplastic Syndrome Transformed into Acute Myeloid Leukemia]. 61
29397844 2018
17
Acute myeloid leukemia presenting as erythema nodosum: A case report. 61
29381943 2017
18
Trisomy 21 with t(5; 11) chromosomal translocation as new unfavorable cytogenetic abnormalities in pediatric acute myeloid leukemia type M2: One case report of nine-year follow-up and literature review. 61
29058300 2017
19
[Distribution of Type 9 T Helper Cells and Expression of Transcriptional Factors in Acute Myeloid Leukemia]. 61
29070098 2017
20
LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. 61
28765931 2017
21
Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype. 61
28194056 2017
22
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia. 61
28406995 2017
23
MYC Amplification in the Form of Ring Chromosomes 8 in Acute Myeloid Leukemia with t(11;16)(q13;p11.2). 61
29393095 2017
24
[Expression of WT1 gene in children with acute myeloid leukemia]. 61
27974109 2016
25
[Correlations Between AML1-ETO Fusion Gene and Clinical Features of Acute Myeloid Leukemia in Sichuan.] 61
28598127 2016
26
Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. 61
27863755 2016
27
Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer. 61
27514505 2016
28
De Novo Philadelphia Positive Acute Myeloid Leukemia with Extensive Basophilia: A Diagnostic Dilemma. 61
27408364 2016
29
Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics. 61
26526573 2016
30
[The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review]. 61
27093993 2016
31
Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo Acute Myeloid Leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31). 61
28249294 2016
32
Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study. 61
27382304 2016
33
Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran. 61
27054117 2016
34
Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. 61
25843763 2015
35
The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia. 61
27352183 2015
36
Treatment-related myelodysplastic syndrome in a child with acute myeloid leukemia and TPMT heterozygosity. 61
25000470 2015
37
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]. 61
25948187 2015
38
Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature. 61
25960852 2015
39
In vivo and in vitro effects of heme oxygenase-1 silencing on the survival of acute myelocytic leukemia-M2 cells. 61
25667656 2015
40
[Prognostic impact of loss of sex chromosomes in children with acute myeloid leukemia subtype M2]. 61
25760843 2015
41
[Subcutaneous myeloid sarcoma in a patient with essential thrombocythemia that transformed into acute myeloid leukemia]. 61
25743142 2015
42
Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors. 61
24897507 2015
43
Successful treatment of a case of acute myeloid leukemia following Langerhans cell histiocytosis in an adolescent: a case report and review of the literature. 61
25932277 2015
44
Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia. 61
26763368 2015
45
Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. 61
25760770 2015
46
Potential crosstalk of Ca2+-ROS-dependent mechanism involved in apoptosis of Kasumi-1 cells mediated by heme oxygenase-1 small interfering RNA. 61
25231232 2014
47
Molecular characterization of complex chromosomal rearrangement: first report of novel t(7;12) (q11;q22) as part of a complex karyotype in de novo AML-M2 case. 61
25286747 2014
48
Acute myelocytic leukemia in a patient with hemophagocytic lymphohistiocytosis: A case report. 61
25364441 2014
49
[FLT3 gene overexpression and its clinical significance in acute myeloid leukemia with AML1/ETO fusion gene positive]. 61
25338557 2014
50
Pleural effusion as an unusual initial presentation of acute myeloid leukemia. 61
25114407 2014

Variations for Acute Myeloblastic Leukemia with Maturation

ClinVar genetic disease variations for Acute Myeloblastic Leukemia with Maturation:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MIR181A1HG NR_040073.1(MIR181A1HG):n.364-18748G>ASNV Pathogenic 427753 rs12406470 1:198796120-198796120 1:198826991-198826991
2 NC_000001.11:g.198807802C>ASNV Pathogenic 427752 rs9660525 1:198776931-198776931 1:198807802-198807802
3 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+1862C>ASNV Pathogenic 427754 rs60639710 1:198867678-198867678 1:198898549-198898549
4 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+1456C>TSNV Pathogenic 427755 rs10800597 1:198868084-198868084 1:198898955-198898955
5 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+26A>GSNV Pathogenic 427756 rs10800598 1:198869514-198869514 1:198900385-198900385

Expression for Acute Myeloblastic Leukemia with Maturation

Search GEO for disease gene expression data for Acute Myeloblastic Leukemia with Maturation.

Pathways for Acute Myeloblastic Leukemia with Maturation

GO Terms for Acute Myeloblastic Leukemia with Maturation

Biological processes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.54 KIT FLT3
2 peptidyl-tyrosine phosphorylation GO:0018108 9.52 KIT FLT3
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.51 KIT FLT3
4 positive regulation of MAPK cascade GO:0043410 9.49 KIT FLT3
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.48 KIT FLT3
6 B cell differentiation GO:0030183 9.46 KIT FLT3
7 positive regulation of kinase activity GO:0033674 9.43 KIT FLT3
8 positive regulation of cell proliferation GO:0008284 9.43 NPM1 KIT FLT3
9 hematopoietic progenitor cell differentiation GO:0002244 9.4 KIT FLT3
10 hemopoiesis GO:0030097 9.37 KIT FLT3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.32 KIT FLT3
12 positive regulation of MAP kinase activity GO:0043406 9.16 KIT FLT3
13 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 8.96 KIT FLT3
14 myeloid progenitor cell differentiation GO:0002318 8.62 KIT FLT3

Molecular functions related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.16 KIT FLT3
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.96 KIT FLT3
3 growth factor binding GO:0019838 8.62 KIT FLT3

Sources for Acute Myeloblastic Leukemia with Maturation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....